Assessment of the long-term safety of anti-tumour necrosis factor therapies is vital for the
safe treatment of inflammatory bowel disease, a disease affecting a young cohort of patients …

With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for
the treatment of Crohn's disease and ulcerative colitis, there have been some concerns …

Inflammatory bowel disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis
(UC), is characterized by inflammation of the gastrointestinal tract. In UC, inflammation is …

The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the
treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of
inflammatory bowel diseases patients leading to an improvement of patient's quality of life …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Nielsen OH, Seidelin JB, Munck LK, Rogler G (Herlev Hospital, University of Copenhagen,
Copenhagen; Køge Hospital, University of Copenhagen, Copenhagen, Denmark; and …

OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel
diseases (IBD) that compromise quality of life and may increase mortality. This study …

The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …